Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease.

Details

Ressource 1Download: 32303185_BIB_0D1D163648E0.pdf (1142.07 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_0D1D163648E0
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Key role of MIF-related neuroinflammation in neurodegeneration and cognitive impairment in Alzheimer's disease.
Journal
Molecular medicine
Author(s)
Nasiri E., Sankowski R., Dietrich H., Oikonomidi A., Huerta P.T., Popp J., Al-Abed Y., Bacher M.
ISSN
1528-3658 (Electronic)
ISSN-L
1076-1551
Publication state
Published
Issued date
17/04/2020
Peer-reviewed
Oui
Volume
26
Number
1
Pages
34
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Macrophage Migration Inhibitory Factor (MIF) is a potent proinflammatory cytokine that promotes the production of other immune mediators. MIF is produced by most cell types in the brain including microglia, astrocytes and neurons. Enhanced expression of MIF might contribute to the persistent activation of glial, chronic neuroinflammation and neurodegeneration. Here, we investigated the effect of MIF on inflammatory markers and spatial learning in a mouse model of sporadic AD and on tau pathology in AD patients.
We examined the effects of MIF deficiency and pharmacological MIF inhibition in vitro and in vivo. In vitro, quantitative PCR and ELISA were used to assess cytokine production of STZ-treated glial cells. In vivo, C57BL/6 mice were subjected to intracerebroventricular streptozotocin injection (3 mg/kg, ICV-STZ). Neuroinflammation and contextual learning performance were assessed using quantitative PCR and fear conditioning, respectively. Pharmacological MIF inhibition was achieved with intraperitoneal injections of ISO-1 (daily, IP, 20 mg/kg in 5% DMSO in 0.9% NaCl) for 4 weeks following ICV-STZ injection. The findings from ISO-1 treated mice were confirmed in MIF knockout C57BL/6. To assess the role of MIF in human AD, cerebrospinal fluid levels of MIF and hyperphosphorylated tau were measured using ELISA.
Administration ICV-STZ resulted in hippocampal dependent cognitive impairment. MIF inhibition with ISO-1 significantly improved the STZ-induced impairment in contextual memory performance, indicating MIF-related inflammation as a major contributor to ICV-STZ-induced memory deficits. Furthermore, inhibition of the MIF resulted in reduced cytokine production in vitro and in vivo. In human subjects with AD at early clinical stages, cerebrospinal fluid levels of MIF were increased in comparison with age-matched controls, and correlated with biomarkers of tau hyper-phosphorylation and neuronal injury hinting at MIF levels as a potential biomarker for early-stage AD.
The present study indicates the key role of MIF in controlling the chronic cytokine release in neuroinflammation related to tau hyperphosphorylation, neurodegeneration, and clinical manifestations of AD, suggesting the potential of MIF inhibition as therapeutic strategy to slow down neurodegeneration and clinical disease progression.
Keywords
Alzheimer’s disease, Astrocyte, Cerebrospinal fluid, Cognitive impairment, ISO-1, Macrophage migration inhibitory factor, Microglia, Neuroinflammation
Pubmed
Open Access
Yes
Create date
25/04/2020 18:44
Last modification date
30/04/2021 6:08
Usage data